This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Smith, U. Search for Related Content Social Bookmarking                   What's this?

Thiazolidinedione-induced effects beyond glycaemic control

Department of Internal Medicine, The Sahlgrenska Academy, S-413 45 Göteborg, Sweden, ulf.smith{at}medic.gu.se

The thiazolidinediones exert their insulin sensitising effect by binding to the nuclear receptors (transcription factors) peroxisome proliferator activated receptor (PPAR) and, to varying degrees, to PPAR. Several different genes are activated by thiazolidinediones, many of which contribute to the increase in insulin sensitivity (eg. an increase in glucose uptake and utilisation, a decrease in gluconeogenesis and in insulin-antagonistic cytokines, such as tumour necrosis factor ). Activation of other genes indirectly reduces insulin resistance by, for example, increasing free fatty acid (FFA) uptake and oxidation resulting in lower circulating FFA levels. The action of thiazolidinediones at PPAR is generally responsible for their insulin sensitising effects while action at PPAR contributes to their lipid lowering effects. Therefore, the relative affinities of the different thiazolidinediones for PPAR and PPAR will also lead to a different spectrum of actions for each agent.

Key Words: diabetic dyslipidaemia • insulin resistance • PPAR receptors • pioglitazone • thiazolidinedione.

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 1 suppl, S24-S27 (2002)
DOI: 10.1177/14746514020020010601


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?